RBM39 Promotes Base Excision Repair to Facilitate the Progression of HCC by Stabilising OGG1 mRNA

Abstract

Targeting base excision repair (BER) has been an attractive strategy in cancer therapeutics. RNA-binding motif protein 39 (RBM39) modulates the alternative splicing of numerous genes involved in cancer occurrence and progression. However, whether and how RBM39 regulates BER in hepatocellular carcinoma (HCC) remain unclear. Here, we found that under oxidative stress, RBM39 degradation or knockdown decreased BER efficiency in HCC cells using a well-designed BER reporter. Further assays showed that RBM39 promoted HCC cell proliferation, migration, and invasion, enhancing cell survival and inhibiting apoptosis. Mechanistically, RBM39 interacted with the mRNA of the essential glycosidase 8-oxoguanine-DNA glycosylase 1 (OGG1), thereby stabilising OGG1 mRNA. This in turn increases OGG1 expression and promotes BER efficiency in HCC. Moreover, data suggested that RBM39 degradation, combined with oxidative damage, could be more effective for HCC treatment than monotherapy, both in vitro and in xenograft mice models. Overall, we demonstrated that RBM39 regulated OGG1 stabilisation and improved BER efficiency, suggesting that combining the RBM39 degradant indisulam with the oxidising agent KBrO₃ could be an emerging strategy for HCC treatment.

Keywords

base excision repair / hepatocellular carcinoma / mRNA stability / OGG1 / RBM39

References

[1] H. Sung, J. Ferlay, R. L. Siegel, et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: a Cancer Journal for Clinicians 71, no. 3 (2021): 209-249.

[2] H. Gilles, T. Garbutt, and J. Landrum, “Hepatocellular Carcinoma,” Critical Care Nursing Clinics of North America 34, no. 3 (2022): 289-301.

[3] A. Forner, M. Reig, and J. Bruix, “Hepatocellular carcinoma,” Lancet 391, no. 10127 (2018): 1301-1314.

[4] L. Geng, Y. Sun, M. Zhu, et al., “The Inhibition of PARG Attenuates DNA Repair in Hepatocellular Carcinoma,” Molecular Biomedicine 4, no. 1 (2023): 3.

[5] A. Xia, W. Yuan, Q. Wang, et al., “The Cancer-Testis lncRNA Lnc-CTHCC Promotes Hepatocellular Carcinogenesis by Binding hnRNP K and Activating YAP1 Transcription,” Nature Cancer 3, no. 2 (2022): 203-218.

[6] B. Arthur and L. Fouad, “Risk Factors of Primary Liver Cancer Initiation Associated With Tumour Initiating Cell Emergence: Novel Targets for Promising Preventive Therapies,” eGastroenterology 1, no. 1 (2023): e100010.

[7] L. Geng, M. Zhu, D. Luo, et al., “TKT-PARP1 Axis Induces Radioresistance by Promoting DNA Double-Strand Break Repair in Hepatocellular Carcinoma,” Oncogene 43 (2024): 682-692.

[8] Y. Lao, X. Cui, Z. Xu, et al., “Glutaryl-CoA Dehydrogenase Suppresses Tumor Progression and Shapes an Anti-Tumor Microenvironment in Hepatocellular Carcinoma,” Journal of Hepatology 81 (2024): 847-861.

[9] B. Li, Y. Li, H. Zhou, et al., “Multiomics Identifies Metabolic Subtypes Based on Fatty Acid Degradation Allocating Personalized Treatment in Hepatocellular Carcinoma,” Hepatology 79, no. 2 (2024): 289-306.

[10] C. Allemani, T. Matsuda, V. Di Carlo, et al., “Global Surveillance of Trends in Cancer Survival 2000-14 (CONCORD-3): Analysis of Individual Records for 37 513 025 Patients Diagnosed With One of 18 Cancers From 322 Population-Based Registries in 71 Countries,” Lancet 391, no. 10125 (2018): 1023-1075.

[11] D. Hanahan, “Hallmarks of Cancer: New Dimensions,” Cancer Discovery 12, no. 1 (2022): 31-46.

[12] D. Gohil, A. H. Sarker, and R. Roy, “Base Excision Repair: Mechanisms and Impact in Biology, Disease, and Medicine,” International Journal of Molecular Sciences 24, no. 18 (2023): 14186.

[13] M. Li, J. Xiong, L. Yang, et al., “Acetylation of p62 Regulates Base Excision Repair Through Interaction With APE1,” Cell Reports 40, no. 3 (2022): 111116.

[14] E. Vickridge, C. C. F. Faraco, and A. Nepveu, “Base Excision Repair Accessory Factors in Senescence Avoidance and Resistance to Treatments,” Cancer Drug Resistance 5, no. 3 (2022): 703-720.

[15] Q. Wu, G. J. Grundy, and J. L. Parsons, “Base Excision Repair and Its Implications to Cancer Therapy,” Essays in Biochemistry 64, no. 5 (2020): 831-843.

[16] G. L. Dianov and U. Hubscher, “Mammalian Base Excision Repair: The Forgotten Archangel,” Nucleic Acids Research 41, no. 6 (2013): 3483-3490.

[17] N. Cooley, R. H. Elder, and A. C. Povey, “The Effect ofMsh2Knockdown on Toxicity Induced Bytert-Butyl-Hydroperoxide, Potassium Bromate, and Hydrogen Peroxide in Base Excision Repair Proficient and Deficient Cells,” BioMed Research International 2013 (2013): 152909.

[18] F. Zhao, J. Zhu, M. Zhang, et al., “OGG1 Aggravates Renal Ischemia-Reperfusion Injury by Repressing PINK1-Mediated Mitophagy,” Cell Proliferation 56, no. 8 (2023): e13418.

[19] Z. Xu, L. Zhang, W. Zhang, et al., “SIRT6 Rescues the Age Related Decline in Base Excision Repair in a PARP1-Dependent Manner,” Cell Cycle 14, no. 2 (2015): 269-276.

[20] Y. Liu, L. Hao, Y. Dong, et al., “Co-Delivery of Siape1 and Melatonin by 125I-Loaded PSMA-Targeted Nanoparticles for the Treatment of Prostate Cancer,” Recent Patents on Anti-Cancer Drug Discovery 19, no. 4 (2024): 503-515, https://doi.org/10.2174/1574892818666230419081414.

[21] T. M. A. Abdel-Fatah, R. Russell, D. Agarwal, et al., “DNA Polymerase β Deficiency Is Linked to Aggressive Breast Cancer: A Comprehensive Analysis of Gene Copy Number, mRNA and Protein Expression in Multiple Cohorts,” Molecular Oncology 8, no. 3 (2014): 520-532.

[22] A. M. Whitaker, M. A. Schaich, M. R. Smith, T. S. Flynn, and B. D. Freudenthal, “Base Excision Repair of Oxidative DNA Damage: From Mechanism to Disease,” Frontiers in Bioscience 22, no. 9 (2017): 1493-1522.

[23] A. Sanjari Moghaddam, M. Nazarzadeh, R. Noroozi, H. Darvish, and A. Mosavi Jarrahi, “XRCC1 and OGG1 Gene Polymorphisms and Breast Cancer: A Systematic Review of Literature,” Iran Journal of Cancer Prevention 9, no. 1 (2016): e3467.

[24] A. W. Caliri, S. Tommasi, and A. Besaratinia, “Relationships Among Smoking, Oxidative Stress, Inflammation, Macromolecular Damage, and Cancer,” Mutation Research, Reviews in Mutation Research 787 (2021): 108365.

[25] Y. Xu, A. Nijhuis, and H. C. Keun, “RNA-Binding Motif Protein 39 (RBM39): An Emerging Cancer Target,” British Journal of Pharmacology 179, no. 12 (2021): 2795-2812.

[26] P. Mehta, C. S. C. Liu, S. Sinha, et al., “Reduced Protein-Coding Transcript Diversity in Severe Dengue Emphasises the Role of Alternative Splicing,” Life Science Alliance 7, no. 8 (2024): e202402683.

[27] C. Xu, X. Chen, X. Zhang, et al., “RNA-Binding Protein 39: A Promising Therapeutic Target for Cancer,” Cell Death Discovery 7, no. 1 (2021): 214, https://doi.org/10.1038/s41420-021-00598-7.

[28] X. Qiao, D. Ma, and X. Zhang, “Identification of Hub Genes and Potential Molecular Mechanisms in MSS/MSI Classifier Primary Colorectal Cancer Based on Multiple Datasets,” Discover Oncology 15, no. 1 (2024): 290, https://doi.org/10.1007/s12672-024-01148-0.

[29] E. Wang, S. X. Lu, A. Pastore, et al., “Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia,” Cancer Cell 35, no. 3 (2019): 369-384.e367.

[30] N. Liu, J. Zhang, W. Chen, W. Ma, and T. Wu, “RBM39 Enhances Cholangiocarcinoma Growth Through EZH2-Mediated WNT7B/β-Catenin Pathway,” Cellular and Molecular Gastroenterology and Hepatology 19 (2024): 101404.

[31] T. Han, M. Goralski, N. Gaskill, et al., “Anticancer Sulfonamides Target Splicing by Inducing RBM39 Degradation via Recruitment to DCAF15,” Science 356, no. 6336 (2017): eaal3755.

[32] I. Mercier, D. M. Gonzales, K. Quann, et al., “CAPER, a Novel Regulator of Human Breast Cancer Progression,” Cell Cycle 13, no. 8 (2014): 1256-1264.

[33] H. Imai, E. K. Chan, K. Kiyosawa, X. D. Fu, and E. M. Tan, “Novel Nuclear Autoantigen With Splicing Factor Motifs Identified With Antibody From Hepatocellular Carcinoma,” Journal of Clinical Investigation 92, no. 5 (1993): 2419-2426.

[34] D. Mossmann, C. Müller, S. Park, et al., “Arginine Reprograms Metabolism in Liver Cancer via RBM39,” Cell 186, no. 23 (2023): 5068-5083.e5023.

[35] A. Geng, J. Sun, H. Tang, et al., “SIRT2 Promotes Base Excision Repair by Transcriptionally Activating OGG1 in an ATM/ATR-Dependent Manner,” Nucleic Acids Research 52, no. 9 (2024): 5107-5120.

[36] G. A. Vitiello, A. Wang, R. M. Lee, et al., “Surgical Resection of Early Stage Hepatocellular Carcinoma Improves Patient Survival at Safety Net Hospitals,” Journal of Surgical Oncology 123, no. 4 (2021): 963-969.

[37] R. Zhang, W. Wang, N. Zhang, et al., “Systematic Pan-Cancer Analysis Identifies RBM39 as an Immunological and Prognostic Biomarker,” Journal of Cellular and Molecular Medicine 26, no. 18 (2022): 4859-4871.

[38] G. P. Copenhaver, Y. K. Kang, N. Putluri, et al., “CAPER Is Vital for Energy and Redox Homeostasis by Integrating Glucose-Induced Mitochondrial Functions via ERR-α-Gabpa and Stress-Induced Adaptive Responses via NF-κB-cMYC,” PLoS Genetics 11, no. 4 (2015): e1005116.

[39] J. Tong, X. Xu, Z. Zhang, et al., “Hypoxia-Induced Long Non-Coding RNA DARS-AS1 Regulates RBM39 Stability to Promote Myeloma Malignancy,” Haematologica 105, no. 6 (2020): 1630-1640.

[40] A. Xia, Q. Yue, M. Zhu, et al., “The Cancer-Testis lncRNA LINC01977 Promotes HCC Progression by Interacting With RBM39 to Prevent Notch2 Ubiquitination,” Cell Death Discovery 9, no. 1 (2023): 169, https://doi.org/10.1038/s41420-023-01459-1.

[41] F. Cui, W. Wang, C. Zhuang, D. He, and P. Wang, “RBM39 Is a Potential Prognostic Biomarker With Functional Significance in Hepatocellular Carcinoma,” Translational Cancer Research 13, no. 4 (2024): 1606-1622.

[42] W. Quarni, C. M. Jablonowski, S. Singh, et al., “Metabolic Reprogramming of Cancer Cells by JMJD6-Mediated Pre-mRNA Splicing Associated With Therapeutic Response to Splicing Inhibitor,” eLife 12 (2024): RP90993.

[43] F. Lemaitre, F. Chakrama, T. O'Grady, et al., “The Transcription Factor c-Jun Inhibits RBM39 to Reprogram Pre-mRNA Splicing During Genotoxic Stress,” Nucleic Acids Research 50, no. 22 (2022): 12768-12789, https://doi.org/10.1093/nar/gkac1130.

[44] T. Visnes, M. Grube, B. M. F. Hanna, C. Benitez-Buelga, A. Cázares-Körner, and T. Helleday, “Targeting BER Enzymes in Cancer Therapy,” DNA Repair 71 (2018): 118-126.

[45] H. Zhang, P. Jiang, M. Lv, Y. Zhao, J. Cui, and J. Chen, “OGG1 Contributes to Hepatocellular Carcinoma by Promoting Cell Cycle-Related Protein Expression and Enhancing DNA Oxidative Damage Repair in Tumor Cells,” Journal of Clinical Laboratory Analysis 36, no. 7 (2022): e24561.

[46] Y. Ma, J. Guo, H. Rao, et al., “The 8-Oxoguanine DNA Glycosylase-Synaptotagmin 7 Pathway Increases Extracellular Vesicle Release and Promotes Tumour Metastasis During Oxidative Stress,” Journal of Extracellular Vesicles 13, no. 9 (2024): e12505.

[47] D. E. Bussiere, L. Xie, H. Srinivas, et al., “Structural Basis of Indisulam-Mediated RBM39 Recruitment to DCAF15 E3 Ligase Complex,” Nature Chemical Biology 16, no. 1 (2019): 15-23.

[48] T. Ando, K. Okamoto, Y. Ueda, et al., “YAP/TAZ Interacts With RBM39 to Confer Resistance Against Indisulam,” Oncogene 13, no. 1 (2024): 25.

[49] I. Baroja, N. C. Kyriakidis, G. Halder, and I. M. Moya, “Expected and Unexpected Effects After Systemic Inhibition of Hippo Transcriptional Output in Cancer,” Nature Communications 15, no. 1 (2024): 2700, https://doi.org/10.1038/s41467-024-46531-1.

[50] J. Lu, H. Jiang, D. Li, et al., “Proximity Labeling, Quantitative Proteomics, and Biochemical Studies Revealed the Molecular Mechanism for the Inhibitory Effect of Indisulam on the Proliferation of Gastric Cancer Cells,” Journal of Proteome Research 20, no. 9 (2021): 4462-4474.

[51] Z. Dou, X. Zhang, W. Su, et al., “Indisulam Exerts Anticancer Effects via Modulation of Transcription, Translation and Alternative Splicing on Human Cervical Cancer Cells,” American Journal of Cancer Research 13, no. 7 (2023): 2922-2937.

[52] S. Singh, W. Quarni, M. Goralski, et al., “Targeting the Spliceosome Through RBM39 Degradation Results in Exceptional Responses in High-Risk Neuroblastoma Models,” Science Advances 7, no. 47 (2021): eabj5405.

[53] A. Nijhuis, A. Sikka, O. Yogev, et al., “Indisulam Targets RNA Splicing and Metabolism to Serve as a Therapeutic Strategy for High-Risk Neuroblastoma,” Nature Communications 13, no. 1 (2022): 1380, https://doi.org/10.1038/s41467-022-28907-3.

[54] X. Zhang, L. Yang, X. Liu, et al., “Regulatory Role of RBM39 in Acute Myeloid Leukemia: Mediation Through the PI3K/AKT Pathway,” Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1871, no. 1 (2024): 119607, https://doi.org/10.1016/j.bbamcr.2023.119607.

[55] T. Ji, Y. Yang, J. Yu, et al., “Targeting RBM39 Through Indisulam Induced Mis-Splicing of mRNA to Exert Anti-Cancer Effects in T-Cell Acute Lymphoblastic Leukemia,” Journal of Experimental & Clinical Cancer Research 43, no. 1 (2024): 205.

[56] G. Mao and J. Liu, “Research on the Mechanism of Exosomes From Different Sources Influencing the Progression of Lung Cancer,” Environmental Toxicology 39, no. 8 (2024): 4231-4248.

[57] C. Lu, Y. Cai, S. Wu, et al., “Deubiquitinating Enzyme USP39 Promotes the Growth and Metastasis of Gastric Cancer Cells by Modulating the Degradation of RNA-Binding Protein RBM39,” Journal of Biological Chemistry 300, no. 10 (2024): 107751.

[58] Y. Zhong, X. Zhang, R. Feng, et al., “OGG1: An Emerging Multifunctional Therapeutic Target for the Treatment of Diseases Caused by Oxidative DNA Damage,” Medicinal Research Reviews 44, no. 6 (2024): 2825-2848.

[59] Z. Xu, M. Zhu, L. Geng, et al., “Targeting NAT10 Attenuates Homologous Recombination via Destabilizing DNA:RNA Hybrids and Overcomes PARP Inhibitor Resistance in Cancers,” Drug Resistance Updates 81 (2025): 101241.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.